The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Bridging the gap between the immune and glutamate hypotheses of schizophrenia and major depression: Potential role of glial NMDA receptor modulators and impaired blood–brain barrier integrity
Abstract
OBJECTIVES: Previous studies have suggested that the pathogenesis of schizophrenia and major depression involves an altered peripheral immune system. It is not clear, however, whether such changes are associated with corresponding neuroinflammatory responses and disturbances of neurotransmission. METHODS: This paper reviews the current state of knowledge about the involvement of immune alterations in schizophrenia and major depression and a possible link to disturbances of glutamatergic transmission. RESULTS: Inflammatory endogenous modulators of the NMDA receptor, the kynurenine pathway metabolites, are potential candidates for such a link. Studies of the blood and cerebrospinal fluid have suggested a schizophrenia-related upregulation of the NMDA receptor antagonist kynurenic acid in astrocytes, analogous to the ketamine psychosis model. Conversely, it has been proposed that there is depression-related microglial synthesis of the NMDA receptor agonist quinolinic acid, which is consistent with the observation that ketamine has therapeutic effects in major depression. Few publications have studied NMDA receptor modulating kynurenines in the brain, however. CONCLUSIONS: Future research on the cerebral cell-type specific distribution of kynurenine metabolites and their brain-regional concentration imbalances will be required to connect peripheral immune changes, the hypotheses of blood-brain barrier dysfunction and glial pathology with concepts of altered neurotransmission in schizophrenia and major depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
Miller, A. H., Maletic, V., & Raison, C. L. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.11.029 · Cited by 3,848
Cytokines sing the blues: inflammation and the pathogenesis of depression
Raison, C. L., Capuron, L., & Miller, A. H. (2006) · Trends in Immunology · doi:10.1016/j.it.2005.11.006 · Cited by 3,009
Common variants conferring risk of schizophrenia
†Genetic Risk and Outcome in Psychosis (GROUP), Stefansson, H., Ophoff, R. A., Steinberg, S., Andreassen, O. A., Cichon, S., Rujescu, D., Werge, T., Pietiläinen, O. P. H., Mors, O., et al. (2009) · Nature · doi:10.1038/nature08186 · Cited by 1,677 · cited 1×
“Similar associations were also found in a recent large genome-wide association study using 2,663 schizophrenia cases compared to 13,498 controls (Stefansson et al. 2009).”
ResultTyring, S., Gottlieb, A., Papp, K., Gordon, K., Leonardi, C., Wang, A., Lalla, D., Woolley, M., Jahreis, A., Zitnik, R., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(05)67763-x · Cited by 1,069 · cited 2×
“…for the hypothesis of a neuroinfl ammatory (co)etiology has come from recent promising clinical trials using cyclooxygease-2 (Cox-2) inhibitors or the tumour necrosis factor α (TNF α ) antagonist etanercept (Enbrel ™ ) to treat acute psychosis and depression (Tyring et al. 2006; M ü ller 2010).”
MethodNMDA receptor hypofunction model of schizophrenia
Olney, J. W., Newcomer, J. W., & Farber, N. B. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(99)00029-1 · Cited by 1,020
The Relationship of Depression and Stressors to Immunological Assays: A Meta-Analytic Review
Zorrilla, E. P., Luborsky, L., McKay, J. R., Rosenthal, R., Houldin, A., Tax, A., McCorkle, R., Seligman, D. A., & Schmidt, K. (2001) · Brain, Behavior, and Immunity · doi:10.1006/brbi.2000.0597 · Cited by 995 · cited 2×
“Because of the percentage and activation of T cells and monocytes in depressed patients, however, it is possible that both acquired and innate immune responses are involved (Zorrilla et al. 2001; Mossner et al. 2007; Drexhage et al. 2010; Miller 2010).”
BackgroundBeckmann, M., Johansen-Berg, H., & Rushworth, M. F. S. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3328-08.2009 · Cited by 789 · cited 1×
“This heterogeneity has been demonstrated by in vivo magnetic resonance imaging studies (Beckmann et al. 2009).”
BackgroundThe neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Vollenweider, F. X., & Kometer, M. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2884 · Cited by 723 · cited 1×
“In contrast, a depression-related activation of the synthesis of the NMDA receptor agonist, quinolinic acid, in microglial cells has been hypothesised, which is in line with the observed therapeutic effects of ketamine in major depression (Vollenweider and Kometer 2010).”
ResultD'Mello, C., Le, T., & Swain, M. G. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3567-08.2009 · Cited by 675
Cited by
Neuroinflammation and psychiatric illness
Najjar, S., Pearlman, D. M., Alper, K., Najjar, A., & Devinsky, O. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-43 · Cited by 733
“5HIAA, 5-Hydroxyindoleacetic acid; α 7nAchR, alpha 7 nicotinic acetylcholine receptors; BBB, blood – brain barrier; IDO, indoleamine-2,3-dioxygenase; IL, interleukin; IFN-γ , interferon gamma; KAT, kynurenine aminotransferase; KMO, kynurenine 3-monooxygenase; KYN, kynurenine; KYNA, kynurenic acid; NMDAR, N-methyl-D-as…”
InfluentialQuinolinic acid, the inescapable neurotoxin
Guillemin, G. J. (2012) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08485.x · Cited by 595
Autoimmune Diseases and Severe Infections as Risk Factors for Mood Disorders: A Nationwide Study
Benros, M. E., Waltoft, B. L., Nordentoft, M., Østergaard, S. D., Eaton, W. W., Krogh, J., & Mortensen, P. B. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.1111 · Cited by 572
Steiner, J., Walter, M., Gos, T., Guillemin, G. J., Bernstein, H.-G., Sarnyai, Z., Mawrin, C., Brisch, R., Bielau, H., zu Schwabedissen, L., et al. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-94 · Cited by 568
“An upregulated production of QUIN by microglia in regions with specific susceptibility to abnormal NMDA throughput would support the hypothesis of an upregulated MPS, and would close the gap between neurochemical imbalances and regional as well as functional in vivo imaging findings in depression.”
BackgroundInfluentialSelf-citationTreatment resistance in psychiatry: state of the art and new directions
Howes, O. D., Thase, M. E., & Pillinger, T. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01200-3 · Cited by 413
Steiner, J., Walter, M., Glanz, W., Sarnyai, Z., Bernstein, H.-G., Vielhaber, S., Kästner, A., Skalej, M., Jordan, W., Schiltz, K., et al. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.86 · Cited by 380
Self-citationBeumer, W., Gibney, S. M., Drexhage, R. C., Pont-Lezica, L., Doorduin, J., Klein, H. C., Steiner, J., Connor, T. J., Harkin, A., Versnel, M. A., et al. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.0212100 · Cited by 347
“Gray arrows, Activation; dotted gray lines with bar at the end, inhibition; black font, potentially neurotoxic; purple font, neutral or not known; bright blue, potentially neuroprotective [8].”
BackgroundFactors influencing the blood-brain barrier permeability
Zhao, Y., Gan, L., Ren, L., Lin, Y., Ma, C., & Lin, X. (2022) · Brain Research · doi:10.1016/j.brainres.2022.147937 · Cited by 291
Savitz, J., Drevets, W. C., Smith, C. M., Victor, T. A., Wurfel, B. E., Bellgowan, P. S., Bodurka, J., Teague, T. K., & Dantzer, R. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.194 · Cited by 272
Najjar, S., Pearlman, D. M., Devinsky, O., Najjar, A., & Zagzag, D. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-142 · Cited by 248
Hou, R., Garner, M., Holmes, C., Osmond, C., Teeling, J., Lau, L., & Baldwin, D. S. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.01.021 · Cited by 191
IDO and Kynurenine Metabolites in Peripheral and CNS Disorders
Huang, Y.-S., Ogbechi, J., Clanchy, F. I., Williams, R. O., & Stone, T. W. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00388 · Cited by 187
Meier, T. B., Drevets, W. C., Wurfel, B. E., Ford, B. N., Morris, H. M., Victor, T. A., Bodurka, J., Teague, T. K., Dantzer, R., & Savitz, J. (2016) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.11.003 · Cited by 175
The role of depressive subtypes within the neuroinflammation hypothesis of major depressive disorder
Woelfer, M., Kasties, V., Kahlfuss, S., & Walter, M. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2018.03.034 · Cited by 171
Involvement of the kynurenine pathway in the pathogenesis of Parkinson's disease
Lim, C. K., Fernández-Gomez, F. J., Braidy, N., Estrada, C., Costa, C., Costa, S., Bessede, A., Fernandez-Villalba, E., Zinger, A., Herrero, M. T., et al. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.12.009 · Cited by 159
“…2008), brain tumours (Adams et al., 2012; Adams et al., 2014), brain trauma (Saito et al., 1993), and neuropsychiatric disorders including depression (Steiner et al., 2011b), suicide (Bay-Richter et al., 2014), schizophrenia (Kegel et al., 2014; Muller et al., 2011), and autism (Essa et al., 2013).”
BackgroundKynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
Ostapiuk, A., & Urbanska, E. M. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13768 · Cited by 142
Steiner, J., Frodl, T., Schiltz, K., Dobrowolny, H., Jacobs, R., Fernandes, B. S., Guest, P. C., Meyer-Lotz, G., Borucki, K., Bahn, S., et al. (2019) · Schizophrenia Bulletin · doi:10.1093/schbul/sbz068 · Cited by 123
Self-citationEffects of inflammation on the kynurenine pathway in schizophrenia—a systematic review
Pedraz-Petrozzi, B., Elyamany, O., Rummel, C., & Mulert, C. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-1721-z · Cited by 119
Schlaaff, K., Dobrowolny, H., Frodl, T., Mawrin, C., Gos, T., Steiner, J., & Bogerts, B. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.04.021 · Cited by 107
Cheng, Y., Wang, Y., Wang, X., Jiang, Z., Zhu, L., & Fang, S. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.893097 · Cited by 110
Gos, T., Myint, A.-M., Schiltz, K., Meyer-Lotz, G., Dobrowolny, H., Busse, S., Müller, U. J., Mawrin, C., Bernstein, H.-G., Bogerts, B., et al. (2014) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2014.05.012 · Cited by 49
Self-citation
Metadata
- Authors
- Steiner, J., Bogerts, B., Sarnyai, Z., Walter, M., Gos, T., Bernstein, H.-G., & Myint, A.-M.
- Venue
- The World Journal of Biological Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2011-06-28
- Volume
- 13
- Issue
- 7
- Pages
- 482-492
- ISSN
- 1562-2975 (ISSN-L)
- 1814-1412
- OpenAlex
- W2113458499
- Cited by
- 160
- References
- 23
- FWCI
- 3.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.